Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




MRI Homepage

Siemens focuses on digitalization at HIMSS Its expanded digital service portfolio will be on display

Prestige Medical Imaging partners with Esaote and Glassbeam Expands portfolio to include MR, ultrasound and analytical software

Fujifilm to unveil latest version of Synapse 3D platform at HIMSS Five new capabilities for advanced visualization

First 7T whole-body MR scanner in Canada installed in Montreal Produces high-resolution images at pixel dimensions measured in tenths of a millimeter

Medic Vision to deploy iQMR in China through new partnership with KAME Address extreme overload of imaging requests in China

Philips and MIM Software collab to streamline radiotherapy treatment planning Integrate portfolios of CT, MR and software solutions

Dennis Durmis MITA names chair of board of directors

Ohio State to treat epilepsy patients with focused ultrasound in world's first clinical trial For when seizures can't be controlled with medication

FDA gives nod to Siemens' MAGNETOM Lumina 3T MR Cost efficient alternative to MAGNETOM Vida MR system

IRADIMED halts Europe-bound deliveries of MR vital sign monitor CE Mark expiring this month

Researchers use zinc to identify prostate cancer under MR

by John W. Mitchell , Senior Correspondent
By relying on a zinc signature, researchers have succeeded in identifying the difference between healthy prostate tissue and cancerous tissue in mice, according to a study just published in the journal Proceedings of the National Academy of Sciences.

“Our contrast-enhanced imaging protocol may offer early detection of prostate cancer, may be able to demonstrate the total glandular burden (pervasiveness) of prostate cancer, and may offer an opportunity to judge the aggressiveness of prostate cancer,” co-author Dr. Neil Rofsky, chairman of radiology and director of translational research at UT Southwestern Medical Center, told HCB News.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

The researchers synthesized a molecule that binds to zinc while also containing a substance that appears as a bright signal in an MR scan. Rofsky said they were able to demonstrate that a mouse model of prostate cancer (abnormal prostate cells) shows lower zinc binding and therefore, less concentration of the accompanying brightening agent.

The result is that prostate cancer appears as a darker focus against the normally brightened gland.

"The potential for translating this method to human clinical imaging is very good, and will be useful for diagnostic purposes. The method may prove useful for monitoring therapies used to treat prostate cancer," added co-author Dr. A. Dean Sherry, Ph.D., director, Advanced Imaging Research Center and professor of chemistry.

The two colleagues became interested in the connection between zinc and cancer from a previous study of a zinc-sensitive MR contrast agent in pancreatic tissue. When they tested the technique on mouse models, they were able to successfully detect small malignant lesions as early as 11 weeks. This makes the noninvasive imaging procedure a potentially useful method for detecting the disease and its progression.

“Based on the knowledge that the highest concentration of zinc in the human body is present in the normal prostate gland, we thought it might be possible to visualize cancerous prostate tissue as a zinc deficient focus surrounded by normal concentrations of zinc in the adjacent, normal glandular tissue,” said Rofsky.

According to the American Cancer Association, one in seven men will be diagnosed with prostate cancer in their lifetime. The disease develops mainly in older men and is rare before the age of 40. Prostate cancer is the second leading cause of death of American men, behind lung cancer. There are about 26,000 deaths a year and about 181,000 new cases of prostate cancer are diagnosed every year.

The two co-authors said the next step in their study will be to research the MR and zinc connection in more complex animals.

MRI Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.